Kura Oncology, Inc. (NASDAQ:KURA) Given Average Rating of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and ten have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $26.3750.

A number of brokerages recently weighed in on KURA. Mizuho lowered their price target on shares of Kura Oncology from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 24th. Lake Street Capital started coverage on shares of Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target for the company. Wall Street Zen raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Saturday. Wedbush reduced their price objective on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research note on Friday, March 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Tuesday, April 21st.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $9.20 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.15 and a quick ratio of 6.14. The firm has a market cap of $816.68 million, a P/E ratio of -2.75 and a beta of 0.32. The firm has a 50 day simple moving average of $8.91 and a 200 day simple moving average of $9.45. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. The business had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. Sell-side analysts predict that Kura Oncology will post -3.23 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kura Oncology

A number of hedge funds and other institutional investors have recently bought and sold shares of KURA. State Street Corp boosted its stake in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after acquiring an additional 1,587,959 shares during the last quarter. Jacobs Levy Equity Management Inc. boosted its stake in Kura Oncology by 101.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock valued at $19,688,000 after acquiring an additional 1,121,228 shares during the last quarter. Renaissance Technologies LLC boosted its position in shares of Kura Oncology by 111.6% during the fourth quarter. Renaissance Technologies LLC now owns 1,830,566 shares of the company’s stock worth $19,020,000 after purchasing an additional 965,256 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares in the last quarter. Finally, Qube Research & Technologies Ltd boosted its position in shares of Kura Oncology by 63.0% during the second quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after purchasing an additional 738,761 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.